HK1215181A1 - γ-羥基丁酸鹽組合物及其治療疾病的用途 - Google Patents

γ-羥基丁酸鹽組合物及其治療疾病的用途

Info

Publication number
HK1215181A1
HK1215181A1 HK16103210.0A HK16103210A HK1215181A1 HK 1215181 A1 HK1215181 A1 HK 1215181A1 HK 16103210 A HK16103210 A HK 16103210A HK 1215181 A1 HK1215181 A1 HK 1215181A1
Authority
HK
Hong Kong
Prior art keywords
disorders
treatment
gamma hydroxybutyrate
hydroxybutyrate compositions
compositions
Prior art date
Application number
HK16103210.0A
Other languages
English (en)
Inventor
克拉克．
．阿爾芬
邁克爾．德斯賈丁
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1215181(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of HK1215181A1 publication Critical patent/HK1215181A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK16103210.0A 2012-12-14 2016-03-18 γ-羥基丁酸鹽組合物及其治療疾病的用途 HK1215181A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737695P 2012-12-14 2012-12-14
PCT/US2013/074954 WO2014093791A1 (en) 2012-12-14 2013-12-13 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Publications (1)

Publication Number Publication Date
HK1215181A1 true HK1215181A1 (zh) 2016-08-19

Family

ID=49596603

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103210.0A HK1215181A1 (zh) 2012-12-14 2016-03-18 γ-羥基丁酸鹽組合物及其治療疾病的用途

Country Status (26)

Country Link
US (9) US8591922B1 (zh)
EP (3) EP2931268B1 (zh)
JP (1) JP6215347B2 (zh)
KR (1) KR102180343B1 (zh)
CN (1) CN105025892B (zh)
AU (1) AU2013359114B2 (zh)
BR (1) BR112015014007A2 (zh)
CA (1) CA2894876C (zh)
CY (2) CY1119918T1 (zh)
DK (2) DK3335709T3 (zh)
ES (2) ES2827005T3 (zh)
HK (1) HK1215181A1 (zh)
HR (1) HRP20201685T1 (zh)
HU (1) HUE051060T2 (zh)
IL (1) IL239355A (zh)
IN (1) IN342829B (zh)
LT (1) LT3335709T (zh)
MX (1) MX366681B (zh)
NO (1) NO3027826T3 (zh)
PL (1) PL2931268T3 (zh)
PT (2) PT2931268T (zh)
SG (1) SG11201504637TA (zh)
SI (1) SI3335709T1 (zh)
TR (1) TR201802271T4 (zh)
TW (2) TWI639425B (zh)
WO (1) WO2014093791A1 (zh)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011232408B2 (en) 2010-03-24 2015-07-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) * 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
KR102279993B1 (ko) 2015-09-23 2021-07-21 엑스더블유파마 리미티드 감마-하이드록시부티르산의 전구체 및 이의 조성물 및 용도
FR3049463B1 (fr) 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
WO2019126218A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
WO2019126215A1 (en) * 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
US20210186907A1 (en) * 2019-12-24 2021-06-24 Jazz Pharmaceuticals Ireland Limited Ghb dosing
TW202139986A (zh) * 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11896573B2 (en) 2020-07-24 2024-02-13 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
WO2022076466A1 (en) 2020-10-05 2022-04-14 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
TW202228666A (zh) 2020-10-16 2022-08-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 使用ghb之治療方法
US11510892B2 (en) 2021-03-19 2022-11-29 XWPharma Ltd. Pharmacokinetics of combined release formulations of a γ-hydroxybutyric acid derivative
EP4308099A1 (en) * 2021-03-20 2024-01-24 Alkem Laboratories Limited A process for the preparation of mixed oxybate salts and polymorphs thereof
US11877992B1 (en) 2021-06-07 2024-01-23 Kelly Kathleen Spinelli Gamma-hydroxybutyrate salts for the treatment of learning disorders
US11877993B1 (en) 2021-06-23 2024-01-23 Kelly Kathleen Spinelli Gamma-hydroxybutyrate salts for the treatment of psychological disorders
WO2023062018A1 (en) 2021-10-11 2023-04-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
WO2023135150A1 (en) 2022-01-11 2023-07-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US20230382880A1 (en) * 2022-04-21 2023-11-30 Zevra Therapeutics, Inc. Gamma-hydroxybutyrate delivering compounds and processes for making and using them

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB922029A (en) 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
US4374441A (en) 1980-05-23 1983-02-22 Book Covers, Inc. Method of making a book cover and pocket element therefor
ZA814854B (en) 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
EP0235408B1 (en) 1984-08-06 1991-01-09 The University Of Toronto Innovations Foundation Pharmaceutical composition and treatment
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
JP2564690B2 (ja) 1990-06-14 1996-12-18 三省製薬 株式会社 メラニン生成抑制外用剤
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1271403B (it) 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
IT1283782B1 (it) 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
US6495598B1 (en) 1997-04-22 2002-12-17 Ophtecs Corporation Perfusate preparation for ophthalmic operation
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
DK1140061T3 (da) 1998-12-23 2003-08-25 Orphan Medical Inc Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
FR2817256B1 (fr) 2000-11-27 2005-07-15 Univ Pasteur Derives de l'acides 4-hydroxybutanoique et de son homologue superieur comme ligands des recepteurs du gamma- hydroxybutyrate (ghb), compositions pharmaceutiques les contenant et utilisations pharmaceutiques
WO2006124609A2 (en) * 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8410304B2 (en) 2009-04-15 2013-04-02 Norac Pharma Process for preparing gamma-hydroxybutyrate
WO2011139271A1 (en) * 2010-05-04 2011-11-10 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number Publication date
TW201429469A (zh) 2014-08-01
US20160058720A1 (en) 2016-03-03
EP3799867A1 (en) 2021-04-07
TWI639425B (zh) 2018-11-01
PL2931268T3 (pl) 2018-06-29
EP2931268A4 (en) 2016-06-01
US20140171506A1 (en) 2014-06-19
CA2894876A1 (en) 2014-06-19
CA2894876C (en) 2017-08-29
CN105025892B (zh) 2018-03-20
US20200338029A1 (en) 2020-10-29
HUE051060T2 (hu) 2021-03-01
BR112015014007A2 (pt) 2017-07-11
MX2015007531A (es) 2016-03-11
US20140171505A1 (en) 2014-06-19
CY1119918T1 (el) 2018-06-27
US9555017B2 (en) 2017-01-31
SI3335709T1 (sl) 2021-01-29
MX366681B (es) 2019-07-19
HRP20201685T1 (hr) 2020-12-25
EP3335709A1 (en) 2018-06-20
AU2013359114B2 (en) 2017-01-19
ES2660056T3 (es) 2018-03-20
CN105025892A (zh) 2015-11-04
PT3335709T (pt) 2020-10-21
CY1123498T1 (el) 2022-03-24
IL239355A (en) 2017-05-29
US9132107B2 (en) 2015-09-15
US10675258B2 (en) 2020-06-09
JP6215347B2 (ja) 2017-10-18
US11554102B2 (en) 2023-01-17
US20190224149A1 (en) 2019-07-25
DK2931268T3 (en) 2018-02-26
EP3335709B1 (en) 2020-08-12
WO2014093791A1 (en) 2014-06-19
IN342829B (zh) 2016-07-01
US20220000815A1 (en) 2022-01-06
US8901173B2 (en) 2014-12-02
TW201831174A (zh) 2018-09-01
NO3027826T3 (zh) 2017-12-16
LT3335709T (lt) 2020-11-25
US8591922B1 (en) 2013-11-26
US10195168B2 (en) 2019-02-05
JP2016503762A (ja) 2016-02-08
KR20150100737A (ko) 2015-09-02
EP2931268B1 (en) 2017-11-22
ES2827005T3 (es) 2021-05-19
PT2931268T (pt) 2018-02-27
DK3335709T3 (da) 2020-10-19
KR102180343B1 (ko) 2020-11-19
SG11201504637TA (en) 2015-07-30
US20170209396A1 (en) 2017-07-27
IL239355A0 (en) 2015-07-30
TWI681770B (zh) 2020-01-11
AU2013359114A1 (en) 2015-07-02
TR201802271T4 (tr) 2018-03-21
EP2931268A1 (en) 2015-10-21
US20240156759A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
HK1215181A1 (zh) γ-羥基丁酸鹽組合物及其治療疾病的用途
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
HK1210957A1 (zh) 外排抑制劑組合物和使用此組合物治療的方法
HK1204461A1 (zh) 用於治療中風的佛波醇酯的組合物和使用方法
EP2827856A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES
IL225239A0 (en) Compounds for the treatment of acne and related diseases
IL242483B (en) Preparations containing omomyc and their use for cancer treatment
IL238177A0 (en) Methods and preparations for the treatment of cancer
HK1198909A1 (zh) 用於治療肝臟疾病和障礙的組合物和方法
HK1217896A1 (zh) 用於治療廣泛性發展障礙的複合物及方法
ZA201408056B (en) Compositions and methods for the treatment of mucositis
ZA201408055B (en) Compositions and methods for the treatment of local pain
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
HK1207293A1 (zh) 用於治療炎症或免疫疾病的組合物
EP2916831A4 (en) RADIOGRAPHIC CONTRAST MEDIUM COMPOSITIONS AND METHODS OF USE FOR TREATING INFLAMMATION AND CONDITIONS ASSOCIATED WITH INFLAMMATION.
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same